Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

517.60 +24.38 (+4.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,983,127
Open 498.00
Bid (Size) 516.01 (2)
Ask (Size) 519.00 (6)
Prev. Close 493.22
Today's Range 494.42 - 518.27
52wk Range 476.49 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield 0.34%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which S&P500 stocks are moving on Monday?
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga

Performance

YTD
-27.6%
-27.6%
1 Month
-10.1%
-10.1%
3 Month
-30.5%
-30.5%
6 Month
-34.3%
-34.3%
1 Year
-48.3%
-48.3%

More News

Read More
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
Via Benzinga
Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For May 30
Via Benzinga
23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Why Regeneron Is Falling And Why You Should Avoid It
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500
Via Stocktwits
Topics Death
Exposures Death
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
Exposures Economy
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN)
Via Chartmill
Topics World Trade
Exposures Tariff
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
Via Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Via Benzinga
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Top S&P500 movers in Friday's session
Via Chartmill
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Via Chartmill
Why Regeneron (REGN) Shares Are Falling Today
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Discover which S&P500 stocks are making waves on Friday.
Via Chartmill
Unity Stock Jumps On Upgrade While Regeneron, Cooper Companies Tank On Downgrades – Top Wall Street Analyst Calls Today
Via Stocktwits
Topics ETFs Economy Stocks
Exposures Economy Tariff US Equities

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 517.60
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 06/09/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 47.51B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 48B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.